Summit Therapeutics is trading 4.5% up at $13.63, moving in line with a broad risk-on rally across U.S. equities despite a lack of company-specific news.
- Major indices are gaining more than 1% following strong manufacturing data and easing geopolitical tensions.
- Market sentiment has been bolstered by currency intervention in Japan and reduced risks regarding strikes in Iran.
- No fresh company-specific catalysts or analyst actions have been reported to directly explain today's price action.